# Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

> **NCT02220738** · PHASE1 · TERMINATED · sponsor: **AbbVie** · enrollment: 19 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** ABT-957
- **OTHER:** Placebo for ABT-957

## Key facts

- **NCT ID:** NCT02220738
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Slow subject enrollment
- **Last updated:** 2021-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02220738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02220738, "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02220738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*